Telomir Publishes Telomir-Zn AMD Preclinical Findings
MIAMI, Fla. — September 17, 2026 Telomir Pharmaceuticals announced the peer-reviewed publication of new preclinical research showing that Telomir-Zn...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
MIAMI, Fla. — September 17, 2026 Telomir Pharmaceuticals announced the peer-reviewed publication of new preclinical research showing that Telomir-Zn...
MIAMI, Fla. — September 14, 2026 Telomir Pharmaceuticals, Inc. announced new research conducted with The Ohio State University College...
BASEL, Switzerland, July 6, 2026 Novartis has announced a landmark agreement to acquire Myricx Bio, a UK-based biotechnology company...
CARLSBAD, California, July 2, 2026 Arima Genomics, Inc., a cancer diagnostics company advancing precision oncology through Hi-C sequencing technology,...
MADRID, Spain & CAMBRIDGE, Mass., July 1, 2026 Oryzon Genomics S.A. announced the successful completion of a €12 million...
CARLSBAD, Calif., July 2, 2026 Arima Genomics, Inc. announced an exclusive distribution partnership with Active Motif Incorporated, granting the...
